You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Advanced Computational Methods for Study of Electromagnetic Compatibility
SBC: DELCROSS TECHNOLOGIES, LLC Topic: AF09BT13Aircraft often are subject to externally generated electromagnetic interference (EMI) comprising high intensity radiated fields of strengths in excess of 1000 V/m generated by radars operating at 400 MHz and above. They also are subject to generally less intense fields produced by internal sources such as handheld radios. This EMI may adversely affect the aircraft’s communication, navigation, an ...
STTR Phase I 2010 Department of DefenseAir Force -
Albumin Nanoparticles Incorporating Piceatannol (PANPs) for ALI/ARDS therapy
SBC: NANO BIOTHERAPEUTICS INC Topic: NHLBISepsis induced ALI ARDS is a devastating syndrome of acute respiratory failure in critically ill patients that accounts for among the highest admission rates in ICU and mortalityDuring STTR Phasewe at Cell Biologics Incdemonstrated that piceatannola naturally occurring anti inflammatory that selectively inhibits Syk tyrosine kinasewhen entrapped in innm albumin nanoparticlesPANPswas therapeuticall ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
A mobile app to reduce treatment-related financial burden for cancer patients
SBC: Vivor, Llc Topic: NCIThere is a fundamental knowledge gap in how to immediately reduce cancer patientstreatment related financial burdenCancer patients pay more out of pocket for their care than those with other chronic illnessesHalf of all elderly cancer patients have high treatment related out of pocket financial burdenThis financial burden has well defined harmful effects even among insured cancer patients includin ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
An Ultra filtrate perfusion bio artificial pancreas for high-density islet replacement without immunosuppression
SBC: Cell-Safe Life Sciences LLC Topic: NIDDKDESCRIPTIONprovided by applicantThe Cell SafeTM is a fundamentally new approach in replacement of dysfunctional insulin producing cells in patients with diabetesby transplantation of new islets in a three dimensional scaffold embedded in a highly compatible bioengineered perfusion system that continuously supplies tissue fluidblood ultrafiltrateso that the cells ae protected from immune rejection ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Bayesian Inference of Spacecraft Geometry and Pose
SBC: VISION SYSTEMS INC Topic: AF17AT007Space platforms are complex dynamical systems and there are many reasons to model them from ground telescope imagery as well as from space-based sensor platforms. One key motivation is to determine the operational state and configuration of the vehicle. Key questions such as did the solar panels fail to deploy, did the object begin to tumble unexpectedly may be addressed by a sufficiently detaile ...
STTR Phase I 2017 Department of DefenseAir Force -
Biocatalytic production of precursors to lutein and zeaxanthin to address age related macular degeneration
SBC: EscaZyme Biochemicals, LLC Topic: NProject Summary Atrophic dry age related macular degeneration AMD is the leading cause of severe loss of vision for those over age Dietary supplements containing lutein and zeaxanthin are recommended by the NEI for those at risk of late AMD There has been a corresponding growth in demand for these two xanthophylls Lutein and zeaxanthin are currently sourced from marigolds grown mostl ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Cblb-based Drugs Against Sepsis and Inflammation
SBC: CELL BIOLOGICS INC Topic: NHLBIAbstract Septicemia poses a major health care challenge. Modern therapies requiring suppression of patients' immune systems, a growing numbers of elderly people in the population, and the emergence of drug-resistant bacteria, have increased the prevalenceand severity of the disease over the past few decades. Current treatments rely on drugs that do not significant reduce morbidity and mortali ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Developing a pocket neuromuscular evaluator
SBC: REHABTEK LLC Topic: NINDSDESCRIPTION (provided by applicant): Disorders of the central nervous system such as spasticity involve both neurological and muscular changes. In clinic, spasticity is routinely evaluated using the Ashworth scale and tendon reflex scale. In general, tendon reflexes have been widely used to evaluate neurological state and diagnose various neurological disorders including stroke, spinal cord injuri ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Developing Therapeutics That Target RAD51 to Treat Leukemia and Lymphoma
SBC: Cyteir Therapeutics, Inc. Topic: NCIDESCRIPTION (provided by applicant): Genomic instability is a hallmark of cancer, yet is underdeveloped as a therapeutic target area The central goal of this program is to develop new cancer therapeutics that target genomic instability as a hallmark of cancer cells, bringing new, cancer-cell selective treatments to the clinical oncology market. Two key challenges in current cancer therapy are mini ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors
SBC: NOVALEX THERAPEUTICS, INC. Topic: NIAIDDESCRIPTION provided by applicant This is a collaborative proposal to develop inhibitors with reduced susceptibility to resistance and improved genotype spectrum of activity against the NS A protease of the Hepatitis C virus HCV Over three percent of the worldandapos s population is infected with the hepatitis C virus HCV Unfortunately the current best treatment is still quite challeng ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health